img

Global Pseudorabies Virus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pseudorabies Virus Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Porcine pseudorabies is an acute infectious disease of pigs caused by Pseudorabies virus (PrV). The disease is fulminant in pigs. It can cause abortion of pregnant sows, stillbirth, infertility of boars, death of a large number of newborn piglets, difficulty in breathing of fattening pigs, and stagnant growth. It is one of the major infectious diseases that harm the global pig industry.
The global Pseudorabies Virus Vaccine market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Pseudorabies Virus Vaccine include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pseudorabies Virus Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pseudorabies Virus Vaccine by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Pseudorabies Virus Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pseudorabies Virus Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Merck
Merial Limited
Boehringer Ingelheim Animal Health (USA) Co., Ltd.
Zoetis
Hipra
Anhui Divinity Biological Products
Wuhan Keqian Biological Co., Ltd.
China Biotechnology Co., Ltd.
CHINA ANIMAL HUSBANDRY INDUSTRY
Sichuan Huashen
Haley
Tianbang
Dabei Nong
Harvey
Preh Bio
Jiangsu Nannong High-Tech Co.
Guangxi Liyuan Biological Co., Ltd.
Jilin Zhengye Bioengineering Group
Jilin Heyuan Biological Engineering Co., Ltd.
Huapai Biological Engineering Group Co., Ltd.
Beijing Xinde Weite Technology Co., Ltd.
Beijing Veterinary Biopharmaceutical Factory
Qilu Animal Health Products Co., Ltd.
Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
Yunnan Biopharmaceutical Co.
Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
Liaoning Yikang Biological Co., Ltd.
Shanghui Huahong Biological Engineering Co., Ltd.
Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
By Type
Inactivated Vaccine
Naturally Deficient Attenuated Vaccine
Genetic Engineering Vaccine
By Application
Government Tender
Market Sales
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pseudorabies Virus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pseudorabies Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pseudorabies Virus Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pseudorabies Virus Vaccine Definition
1.2 Market by Type
1.2.1 Global Pseudorabies Virus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Inactivated Vaccine
1.2.3 Naturally Deficient Attenuated Vaccine
1.2.4 Genetic Engineering Vaccine
1.3 Market Segment by Application
1.3.1 Global Pseudorabies Virus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Government Tender
1.3.3 Market Sales
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pseudorabies Virus Vaccine Sales
2.1 Global Pseudorabies Virus Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Pseudorabies Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pseudorabies Virus Vaccine Revenue by Region
2.3.1 Global Pseudorabies Virus Vaccine Revenue by Region (2018-2024)
2.3.2 Global Pseudorabies Virus Vaccine Revenue by Region (2024-2034)
2.4 Global Pseudorabies Virus Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pseudorabies Virus Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pseudorabies Virus Vaccine Sales Quantity by Region
2.6.1 Global Pseudorabies Virus Vaccine Sales Quantity by Region (2018-2024)
2.6.2 Global Pseudorabies Virus Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pseudorabies Virus Vaccine Sales Quantity by Manufacturers
3.1.1 Global Pseudorabies Virus Vaccine Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pseudorabies Virus Vaccine Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pseudorabies Virus Vaccine Sales in 2022
3.2 Global Pseudorabies Virus Vaccine Revenue by Manufacturers
3.2.1 Global Pseudorabies Virus Vaccine Revenue by Manufacturers (2018-2024)
3.2.2 Global Pseudorabies Virus Vaccine Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pseudorabies Virus Vaccine Revenue in 2022
3.3 Global Pseudorabies Virus Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Pseudorabies Virus Vaccine, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pseudorabies Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pseudorabies Virus Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pseudorabies Virus Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Pseudorabies Virus Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pseudorabies Virus Vaccine Sales Quantity by Type
4.1.1 Global Pseudorabies Virus Vaccine Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pseudorabies Virus Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pseudorabies Virus Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pseudorabies Virus Vaccine Revenue by Type
4.2.1 Global Pseudorabies Virus Vaccine Historical Revenue by Type (2018-2024)
4.2.2 Global Pseudorabies Virus Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Pseudorabies Virus Vaccine Price by Type
4.3.1 Global Pseudorabies Virus Vaccine Price by Type (2018-2024)
4.3.2 Global Pseudorabies Virus Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pseudorabies Virus Vaccine Sales Quantity by Application
5.1.1 Global Pseudorabies Virus Vaccine Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pseudorabies Virus Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pseudorabies Virus Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pseudorabies Virus Vaccine Revenue by Application
5.2.1 Global Pseudorabies Virus Vaccine Historical Revenue by Application (2018-2024)
5.2.2 Global Pseudorabies Virus Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Pseudorabies Virus Vaccine Price by Application
5.3.1 Global Pseudorabies Virus Vaccine Price by Application (2018-2024)
5.3.2 Global Pseudorabies Virus Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pseudorabies Virus Vaccine Sales by Company
6.1.1 North America Pseudorabies Virus Vaccine Revenue by Company (2018-2024)
6.1.2 North America Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024)
6.2 North America Pseudorabies Virus Vaccine Market Size by Type
6.2.1 North America Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Pseudorabies Virus Vaccine Revenue by Type (2018-2034)
6.3 North America Pseudorabies Virus Vaccine Market Size by Application
6.3.1 North America Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Pseudorabies Virus Vaccine Revenue by Application (2018-2034)
6.4 North America Pseudorabies Virus Vaccine Market Size by Country
6.4.1 North America Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pseudorabies Virus Vaccine Revenue by Country (2018-2034)
6.4.3 North America Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pseudorabies Virus Vaccine Sales by Company
7.1.1 Europe Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024)
7.1.2 Europe Pseudorabies Virus Vaccine Revenue by Company (2018-2024)
7.2 Europe Pseudorabies Virus Vaccine Market Size by Type
7.2.1 Europe Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Pseudorabies Virus Vaccine Revenue by Type (2018-2034)
7.3 Europe Pseudorabies Virus Vaccine Market Size by Application
7.3.1 Europe Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Pseudorabies Virus Vaccine Revenue by Application (2018-2034)
7.4 Europe Pseudorabies Virus Vaccine Market Size by Country
7.4.1 Europe Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pseudorabies Virus Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pseudorabies Virus Vaccine Sales by Company
8.1.1 China Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024)
8.1.2 China Pseudorabies Virus Vaccine Revenue by Company (2018-2024)
8.2 China Pseudorabies Virus Vaccine Market Size by Type
8.2.1 China Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Pseudorabies Virus Vaccine Revenue by Type (2018-2034)
8.3 China Pseudorabies Virus Vaccine Market Size by Application
8.3.1 China Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Pseudorabies Virus Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pseudorabies Virus Vaccine Sales by Company
9.1.1 APAC Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024)
9.1.2 APAC Pseudorabies Virus Vaccine Revenue by Company (2018-2024)
9.2 APAC Pseudorabies Virus Vaccine Market Size by Type
9.2.1 APAC Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Pseudorabies Virus Vaccine Revenue by Type (2018-2034)
9.3 APAC Pseudorabies Virus Vaccine Market Size by Application
9.3.1 APAC Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Pseudorabies Virus Vaccine Revenue by Application (2018-2034)
9.4 APAC Pseudorabies Virus Vaccine Market Size by Region
9.4.1 APAC Pseudorabies Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pseudorabies Virus Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Pseudorabies Virus Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Merck Pseudorabies Virus Vaccine Products and Services
11.1.5 Merck Pseudorabies Virus Vaccine SWOT Analysis
11.1.6 Merck Recent Developments
11.2 Merial Limited
11.2.1 Merial Limited Company Information
11.2.2 Merial Limited Overview
11.2.3 Merial Limited Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Merial Limited Pseudorabies Virus Vaccine Products and Services
11.2.5 Merial Limited Pseudorabies Virus Vaccine SWOT Analysis
11.2.6 Merial Limited Recent Developments
11.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd.
11.3.1 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Company Information
11.3.2 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Overview
11.3.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.3.5 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
11.3.6 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Recent Developments
11.4 Zoetis
11.4.1 Zoetis Company Information
11.4.2 Zoetis Overview
11.4.3 Zoetis Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Zoetis Pseudorabies Virus Vaccine Products and Services
11.4.5 Zoetis Pseudorabies Virus Vaccine SWOT Analysis
11.4.6 Zoetis Recent Developments
11.5 Hipra
11.5.1 Hipra Company Information
11.5.2 Hipra Overview
11.5.3 Hipra Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Hipra Pseudorabies Virus Vaccine Products and Services
11.5.5 Hipra Pseudorabies Virus Vaccine SWOT Analysis
11.5.6 Hipra Recent Developments
11.6 Anhui Divinity Biological Products
11.6.1 Anhui Divinity Biological Products Company Information
11.6.2 Anhui Divinity Biological Products Overview
11.6.3 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Products and Services
11.6.5 Anhui Divinity Biological Products Pseudorabies Virus Vaccine SWOT Analysis
11.6.6 Anhui Divinity Biological Products Recent Developments
11.7 Wuhan Keqian Biological Co., Ltd.
11.7.1 Wuhan Keqian Biological Co., Ltd. Company Information
11.7.2 Wuhan Keqian Biological Co., Ltd. Overview
11.7.3 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.7.5 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
11.7.6 Wuhan Keqian Biological Co., Ltd. Recent Developments
11.8 China Biotechnology Co., Ltd.
11.8.1 China Biotechnology Co., Ltd. Company Information
11.8.2 China Biotechnology Co., Ltd. Overview
11.8.3 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.8.5 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
11.8.6 China Biotechnology Co., Ltd. Recent Developments
11.9 CHINA ANIMAL HUSBANDRY INDUSTRY
11.9.1 CHINA ANIMAL HUSBANDRY INDUSTRY Company Information
11.9.2 CHINA ANIMAL HUSBANDRY INDUSTRY Overview
11.9.3 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Products and Services
11.9.5 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine SWOT Analysis
11.9.6 CHINA ANIMAL HUSBANDRY INDUSTRY Recent Developments
11.10 Sichuan Huashen
11.10.1 Sichuan Huashen Company Information
11.10.2 Sichuan Huashen Overview
11.10.3 Sichuan Huashen Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Sichuan Huashen Pseudorabies Virus Vaccine Products and Services
11.10.5 Sichuan Huashen Pseudorabies Virus Vaccine SWOT Analysis
11.10.6 Sichuan Huashen Recent Developments
11.11 Haley
11.11.1 Haley Company Information
11.11.2 Haley Overview
11.11.3 Haley Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Haley Pseudorabies Virus Vaccine Products and Services
11.11.5 Haley Recent Developments
11.12 Tianbang
11.12.1 Tianbang Company Information
11.12.2 Tianbang Overview
11.12.3 Tianbang Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Tianbang Pseudorabies Virus Vaccine Products and Services
11.12.5 Tianbang Recent Developments
11.13 Dabei Nong
11.13.1 Dabei Nong Company Information
11.13.2 Dabei Nong Overview
11.13.3 Dabei Nong Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Dabei Nong Pseudorabies Virus Vaccine Products and Services
11.13.5 Dabei Nong Recent Developments
11.14 Harvey
11.14.1 Harvey Company Information
11.14.2 Harvey Overview
11.14.3 Harvey Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Harvey Pseudorabies Virus Vaccine Products and Services
11.14.5 Harvey Recent Developments
11.15 Preh Bio
11.15.1 Preh Bio Company Information
11.15.2 Preh Bio Overview
11.15.3 Preh Bio Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Preh Bio Pseudorabies Virus Vaccine Products and Services
11.15.5 Preh Bio Recent Developments
11.16 Jiangsu Nannong High-Tech Co.
11.16.1 Jiangsu Nannong High-Tech Co. Company Information
11.16.2 Jiangsu Nannong High-Tech Co. Overview
11.16.3 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Products and Services
11.16.5 Jiangsu Nannong High-Tech Co. Recent Developments
11.17 Guangxi Liyuan Biological Co., Ltd.
11.17.1 Guangxi Liyuan Biological Co., Ltd. Company Information
11.17.2 Guangxi Liyuan Biological Co., Ltd. Overview
11.17.3 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.17.5 Guangxi Liyuan Biological Co., Ltd. Recent Developments
11.18 Jilin Zhengye Bioengineering Group
11.18.1 Jilin Zhengye Bioengineering Group Company Information
11.18.2 Jilin Zhengye Bioengineering Group Overview
11.18.3 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.18.4 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Products and Services
11.18.5 Jilin Zhengye Bioengineering Group Recent Developments
11.19 Jilin Heyuan Biological Engineering Co., Ltd.
11.19.1 Jilin Heyuan Biological Engineering Co., Ltd. Company Information
11.19.2 Jilin Heyuan Biological Engineering Co., Ltd. Overview
11.19.3 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.19.4 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.19.5 Jilin Heyuan Biological Engineering Co., Ltd. Recent Developments
11.20 Huapai Biological Engineering Group Co., Ltd.
11.20.1 Huapai Biological Engineering Group Co., Ltd. Company Information
11.20.2 Huapai Biological Engineering Group Co., Ltd. Overview
11.20.3 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.20.4 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.20.5 Huapai Biological Engineering Group Co., Ltd. Recent Developments
11.21 Beijing Xinde Weite Technology Co., Ltd.
11.21.1 Beijing Xinde Weite Technology Co., Ltd. Company Information
11.21.2 Beijing Xinde Weite Technology Co., Ltd. Overview
11.21.3 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.21.4 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.21.5 Beijing Xinde Weite Technology Co., Ltd. Recent Developments
11.22 Beijing Veterinary Biopharmaceutical Factory
11.22.1 Beijing Veterinary Biopharmaceutical Factory Company Information
11.22.2 Beijing Veterinary Biopharmaceutical Factory Overview
11.22.3 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.22.4 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Products and Services
11.22.5 Beijing Veterinary Biopharmaceutical Factory Recent Developments
11.23 Qilu Animal Health Products Co., Ltd.
11.23.1 Qilu Animal Health Products Co., Ltd. Company Information
11.23.2 Qilu Animal Health Products Co., Ltd. Overview
11.23.3 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.23.4 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.23.5 Qilu Animal Health Products Co., Ltd. Recent Developments
11.24 Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
11.24.1 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Company Information
11.24.2 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Overview
11.24.3 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.24.4 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.24.5 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Recent Developments
11.25 Yunnan Biopharmaceutical Co.
11.25.1 Yunnan Biopharmaceutical Co. Company Information
11.25.2 Yunnan Biopharmaceutical Co. Overview
11.25.3 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.25.4 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Products and Services
11.25.5 Yunnan Biopharmaceutical Co. Recent Developments
11.26 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
11.26.1 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Company Information
11.26.2 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Overview
11.26.3 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.26.4 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.26.5 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Recent Developments
11.27 Liaoning Yikang Biological Co., Ltd.
11.27.1 Liaoning Yikang Biological Co., Ltd. Company Information
11.27.2 Liaoning Yikang Biological Co., Ltd. Overview
11.27.3 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.27.4 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.27.5 Liaoning Yikang Biological Co., Ltd. Recent Developments
11.28 Shanghui Huahong Biological Engineering Co., Ltd.
11.28.1 Shanghui Huahong Biological Engineering Co., Ltd. Company Information
11.28.2 Shanghui Huahong Biological Engineering Co., Ltd. Overview
11.28.3 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.28.4 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.28.5 Shanghui Huahong Biological Engineering Co., Ltd. Recent Developments
11.29 Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
11.29.1 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Company Information
11.29.2 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Overview
11.29.3 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.29.4 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.29.5 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Recent Developments
11.30 Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
11.30.1 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Company Information
11.30.2 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Overview
11.30.3 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.30.4 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Products and Services
11.30.5 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pseudorabies Virus Vaccine Value Chain Analysis
12.2 Pseudorabies Virus Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pseudorabies Virus Vaccine Production Mode & Process
12.4 Pseudorabies Virus Vaccine Sales and Marketing
12.4.1 Pseudorabies Virus Vaccine Sales Channels
12.4.2 Pseudorabies Virus Vaccine Distributors
12.5 Pseudorabies Virus Vaccine Customers
13 Market Dynamics
13.1 Pseudorabies Virus Vaccine Industry Trends
13.2 Pseudorabies Virus Vaccine Market Drivers
13.3 Pseudorabies Virus Vaccine Market Challenges
13.4 Pseudorabies Virus Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pseudorabies Virus Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Inactivated Vaccine
Table 3. Major Manufacturers of Naturally Deficient Attenuated Vaccine
Table 4. Major Manufacturers of Genetic Engineering Vaccine
Table 5. Global Pseudorabies Virus Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Pseudorabies Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Pseudorabies Virus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Pseudorabies Virus Vaccine Revenue Market Share by Region (2018-2024)
Table 9. Global Pseudorabies Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Pseudorabies Virus Vaccine Revenue Market Share by Region (2024-2034)
Table 11. Global Pseudorabies Virus Vaccine Sales Quantity by Region: 2018 VS 2022 VS 2034 (M Doses)
Table 12. Global Pseudorabies Virus Vaccine Sales by Region (2018-2024) & (M Doses)
Table 13. Global Pseudorabies Virus Vaccine Sales Market Share by Region (2018-2024)
Table 14. Global Pseudorabies Virus Vaccine Sales by Region (2024-2034) & (M Doses)
Table 15. Global Pseudorabies Virus Vaccine Sales Market Share by Region (2024-2034)
Table 16. Global Pseudorabies Virus Vaccine Sales Quantity by Manufacturers (2018-2024) & (M Doses)
Table 17. Global Pseudorabies Virus Vaccine Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Pseudorabies Virus Vaccine Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Pseudorabies Virus Vaccine Revenue Share by Manufacturers (2018-2024)
Table 20. Global Pseudorabies Virus Vaccine Price by Manufacturers 2018-2024 (USD/Doses)
Table 21. Global Key Players of Pseudorabies Virus Vaccine, Industry Ranking, 2021 VS 2022
Table 22. Global Pseudorabies Virus Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Pseudorabies Virus Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pseudorabies Virus Vaccine as of 2022)
Table 24. Global Key Manufacturers of Pseudorabies Virus Vaccine, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Pseudorabies Virus Vaccine, Product Offered and Application
Table 26. Global Key Manufacturers of Pseudorabies Virus Vaccine, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 29. Global Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 30. Global Pseudorabies Virus Vaccine Sales Quantity Share by Type (2018-2024)
Table 31. Global Pseudorabies Virus Vaccine Sales Quantity Share by Type (2024-2034)
Table 32. Global Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Pseudorabies Virus Vaccine Revenue Share by Type (2018-2024)
Table 35. Global Pseudorabies Virus Vaccine Revenue Share by Type (2024-2034)
Table 36. Pseudorabies Virus Vaccine Price by Type (2018-2024) & (USD/Doses)
Table 37. Global Pseudorabies Virus Vaccine Price Forecast by Type (2024-2034) & (USD/Doses)
Table 38. Global Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 39. Global Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 40. Global Pseudorabies Virus Vaccine Sales Quantity Share by Application (2018-2024)
Table 41. Global Pseudorabies Virus Vaccine Sales Quantity Share by Application (2024-2034)
Table 42. Global Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Pseudorabies Virus Vaccine Revenue Share by Application (2018-2024)
Table 45. Global Pseudorabies Virus Vaccine Revenue Share by Application (2024-2034)
Table 46. Pseudorabies Virus Vaccine Price by Application (2018-2024) & (USD/Doses)
Table 47. Global Pseudorabies Virus Vaccine Price Forecast by Application (2024-2034) & (USD/Doses)
Table 48. North America Pseudorabies Virus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024) & (M Doses)
Table 50. North America Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 51. North America Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 52. North America Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 55. North America Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 56. North America Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Pseudorabies Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Pseudorabies Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2024) & (M Doses)
Table 62. North America Pseudorabies Virus Vaccine Sales Quantity by Country (2024-2034) & (M Doses)
Table 63. Europe Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024) & (M Doses)
Table 64. Europe Pseudorabies Virus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 66. Europe Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 67. Europe Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 70. Europe Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 71. Europe Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Pseudorabies Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Pseudorabies Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2024) & (M Doses)
Table 77. Europe Pseudorabies Virus Vaccine Sales Quantity by Country (2024-2034) & (M Doses)
Table 78. China Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024) & (M Doses)
Table 79. China Pseudorabies Virus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 81. China Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 82. China Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 85. China Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 86. China Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024) & (M Doses)
Table 89. APAC Pseudorabies Virus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 91. APAC Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 92. APAC Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 95. APAC Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 96. APAC Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Pseudorabies Virus Vaccine Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Pseudorabies Virus Vaccine Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Pseudorabies Virus Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Pseudorabies Virus Vaccine Sales Quantity by Region (2018-2024) & (M Doses)
Table 102. APAC Pseudorabies Virus Vaccine Sales Quantity by Region (2024-2034) & (M Doses)
Table 103. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Company (2018-2024) & (M Doses)
Table 104. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Type (2018-2024) & (M Doses)
Table 106. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Type (2024-2034) & (M Doses)
Table 107. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Application (2018-2024) & (M Doses)
Table 110. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Application (2024-2034) & (M Doses)
Table 111. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Country (2018-2024) & (M Doses)
Table 117. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity by Country (2024-2034) & (M Doses)
Table 118. Merck Company Information
Table 119. Merck Description and Overview
Table 120. Merck Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 121. Merck Pseudorabies Virus Vaccine Product and Services
Table 122. Merck Pseudorabies Virus Vaccine SWOT Analysis
Table 123. Merck Recent Developments
Table 124. Merial Limited Company Information
Table 125. Merial Limited Description and Overview
Table 126. Merial Limited Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 127. Merial Limited Pseudorabies Virus Vaccine Product and Services
Table 128. Merial Limited Pseudorabies Virus Vaccine SWOT Analysis
Table 129. Merial Limited Recent Developments
Table 130. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Company Information
Table 131. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Description and Overview
Table 132. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 133. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 134. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
Table 135. Boehringer Ingelheim Animal Health (USA) Co., Ltd. Recent Developments
Table 136. Zoetis Company Information
Table 137. Zoetis Description and Overview
Table 138. Zoetis Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 139. Zoetis Pseudorabies Virus Vaccine Product and Services
Table 140. Zoetis Pseudorabies Virus Vaccine SWOT Analysis
Table 141. Zoetis Recent Developments
Table 142. Hipra Company Information
Table 143. Hipra Description and Overview
Table 144. Hipra Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 145. Hipra Pseudorabies Virus Vaccine Product and Services
Table 146. Hipra Pseudorabies Virus Vaccine SWOT Analysis
Table 147. Hipra Recent Developments
Table 148. Anhui Divinity Biological Products Company Information
Table 149. Anhui Divinity Biological Products Description and Overview
Table 150. Anhui Divinity Biological Products Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 151. Anhui Divinity Biological Products Pseudorabies Virus Vaccine Product and Services
Table 152. Anhui Divinity Biological Products Pseudorabies Virus Vaccine SWOT Analysis
Table 153. Anhui Divinity Biological Products Recent Developments
Table 154. Wuhan Keqian Biological Co., Ltd. Company Information
Table 155. Wuhan Keqian Biological Co., Ltd. Description and Overview
Table 156. Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 157. Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 158. Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
Table 159. Wuhan Keqian Biological Co., Ltd. Recent Developments
Table 160. China Biotechnology Co., Ltd. Company Information
Table 161. China Biotechnology Co., Ltd. Description and Overview
Table 162. China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 163. China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 164. China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine SWOT Analysis
Table 165. China Biotechnology Co., Ltd. Recent Developments
Table 166. CHINA ANIMAL HUSBANDRY INDUSTRY Company Information
Table 167. CHINA ANIMAL HUSBANDRY INDUSTRY Description and Overview
Table 168. CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 169. CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Product and Services
Table 170. CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine SWOT Analysis
Table 171. CHINA ANIMAL HUSBANDRY INDUSTRY Recent Developments
Table 172. Sichuan Huashen Company Information
Table 173. Sichuan Huashen Description and Overview
Table 174. Sichuan Huashen Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 175. Sichuan Huashen Pseudorabies Virus Vaccine Product and Services
Table 176. Sichuan Huashen Pseudorabies Virus Vaccine SWOT Analysis
Table 177. Sichuan Huashen Recent Developments
Table 178. Haley Company Information
Table 179. Haley Description and Overview
Table 180. Haley Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 181. Haley Pseudorabies Virus Vaccine Product and Services
Table 182. Haley Recent Developments
Table 183. Tianbang Company Information
Table 184. Tianbang Description and Overview
Table 185. Tianbang Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 186. Tianbang Pseudorabies Virus Vaccine Product and Services
Table 187. Tianbang Recent Developments
Table 188. Dabei Nong Company Information
Table 189. Dabei Nong Description and Overview
Table 190. Dabei Nong Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 191. Dabei Nong Pseudorabies Virus Vaccine Product and Services
Table 192. Dabei Nong Recent Developments
Table 193. Harvey Company Information
Table 194. Harvey Description and Overview
Table 195. Harvey Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 196. Harvey Pseudorabies Virus Vaccine Product and Services
Table 197. Harvey Recent Developments
Table 198. Preh Bio Company Information
Table 199. Preh Bio Description and Overview
Table 200. Preh Bio Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 201. Preh Bio Pseudorabies Virus Vaccine Product and Services
Table 202. Preh Bio Recent Developments
Table 203. Jiangsu Nannong High-Tech Co. Company Information
Table 204. Jiangsu Nannong High-Tech Co. Description and Overview
Table 205. Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 206. Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Product and Services
Table 207. Jiangsu Nannong High-Tech Co. Recent Developments
Table 208. Guangxi Liyuan Biological Co., Ltd. Company Information
Table 209. Guangxi Liyuan Biological Co., Ltd. Description and Overview
Table 210. Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 211. Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 212. Guangxi Liyuan Biological Co., Ltd. Recent Developments
Table 213. Jilin Zhengye Bioengineering Group Company Information
Table 214. Jilin Zhengye Bioengineering Group Description and Overview
Table 215. Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 216. Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Product and Services
Table 217. Jilin Zhengye Bioengineering Group Recent Developments
Table 218. Jilin Heyuan Biological Engineering Co., Ltd. Company Information
Table 219. Jilin Heyuan Biological Engineering Co., Ltd. Description and Overview
Table 220. Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 221. Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 222. Jilin Heyuan Biological Engineering Co., Ltd. Recent Developments
Table 223. Huapai Biological Engineering Group Co., Ltd. Company Information
Table 224. Huapai Biological Engineering Group Co., Ltd. Description and Overview
Table 225. Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 226. Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 227. Huapai Biological Engineering Group Co., Ltd. Recent Developments
Table 228. Beijing Xinde Weite Technology Co., Ltd. Company Information
Table 229. Beijing Xinde Weite Technology Co., Ltd. Description and Overview
Table 230. Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 231. Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 232. Beijing Xinde Weite Technology Co., Ltd. Recent Developments
Table 233. Beijing Veterinary Biopharmaceutical Factory Company Information
Table 234. Beijing Veterinary Biopharmaceutical Factory Description and Overview
Table 235. Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 236. Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Product and Services
Table 237. Beijing Veterinary Biopharmaceutical Factory Recent Developments
Table 238. Qilu Animal Health Products Co., Ltd. Company Information
Table 239. Qilu Animal Health Products Co., Ltd. Description and Overview
Table 240. Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 241. Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 242. Qilu Animal Health Products Co., Ltd. Recent Developments
Table 243. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Company Information
Table 244. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Description and Overview
Table 245. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 246. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 247. Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Recent Developments
Table 248. Yunnan Biopharmaceutical Co. Company Information
Table 249. Yunnan Biopharmaceutical Co. Description and Overview
Table 250. Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 251. Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Product and Services
Table 252. Yunnan Biopharmaceutical Co. Recent Developments
Table 253. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Company Information
Table 254. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Description and Overview
Table 255. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 256. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 257. Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Recent Developments
Table 258. Liaoning Yikang Biological Co., Ltd. Company Information
Table 259. Liaoning Yikang Biological Co., Ltd. Description and Overview
Table 260. Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 261. Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 262. Liaoning Yikang Biological Co., Ltd. Recent Developments
Table 263. Shanghui Huahong Biological Engineering Co., Ltd. Company Information
Table 264. Shanghui Huahong Biological Engineering Co., Ltd. Description and Overview
Table 265. Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 266. Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 267. Shanghui Huahong Biological Engineering Co., Ltd. Recent Developments
Table 268. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Company Information
Table 269. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Description and Overview
Table 270. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 271. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 272. Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Recent Developments
Table 273. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Company Information
Table 274. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Description and Overview
Table 275. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Doses) and Gross Margin (2018-2024)
Table 276. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product and Services
Table 277. Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Recent Developments
Table 278. Key Raw Materials Lists
Table 279. Raw Materials Key Suppliers Lists
Table 280. Pseudorabies Virus Vaccine Distributors List
Table 281. Pseudorabies Virus Vaccine Customers List
Table 282. Pseudorabies Virus Vaccine Market Trends
Table 283. Pseudorabies Virus Vaccine Market Drivers
Table 284. Pseudorabies Virus Vaccine Market Challenges
Table 285. Pseudorabies Virus Vaccine Market Restraints
Table 286. Research Programs/Design for This Report
Table 287. Key Data Information from Secondary Sources
Table 288. Key Data Information from Primary Sources
List of Figures
Figure 1. Pseudorabies Virus Vaccine Product Picture
Figure 2. Global Pseudorabies Virus Vaccine Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pseudorabies Virus Vaccine Market Share by Type in 2022 & 2034
Figure 4. Inactivated Vaccine Product Picture
Figure 5. Naturally Deficient Attenuated Vaccine Product Picture
Figure 6. Genetic Engineering Vaccine Product Picture
Figure 7. Global Pseudorabies Virus Vaccine Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Pseudorabies Virus Vaccine Market Share by Application in 2022 & 2034
Figure 9. Government Tender
Figure 10. Market Sales
Figure 11. Pseudorabies Virus Vaccine Report Years Considered
Figure 12. Global Pseudorabies Virus Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Pseudorabies Virus Vaccine Revenue 2018-2034 (US$ Million)
Figure 14. Global Pseudorabies Virus Vaccine Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Pseudorabies Virus Vaccine Sales Quantity 2018-2034 (M Doses)
Figure 16. Global Pseudorabies Virus Vaccine Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Pseudorabies Virus Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Pseudorabies Virus Vaccine Sales Quantity YoY (2018-2034) & (M Doses)
Figure 19. North America Pseudorabies Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Pseudorabies Virus Vaccine Sales Quantity YoY (2018-2034) & (M Doses)
Figure 21. Europe Pseudorabies Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Pseudorabies Virus Vaccine Sales Quantity YoY (2018-2034) & (M Doses)
Figure 23. China Pseudorabies Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Pseudorabies Virus Vaccine Sales Quantity YoY (2018-2034) & (M Doses)
Figure 25. APAC Pseudorabies Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Sales Quantity YoY (2018-2034) & (M Doses)
Figure 27. Middle East, Africa and Latin America Pseudorabies Virus Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Pseudorabies Virus Vaccine Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Pseudorabies Virus Vaccine Revenue in 2022
Figure 30. Pseudorabies Virus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Pseudorabies Virus Vaccine Sales Quantity Market Share by Type (2018-2034)_x0